Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice - Gallo, L A; Ward, M S; Fotheringham, A K; Zhuang, A; Borg, D J; Flemming, N B; Harvie, B M; Kinneally, T L; Yeh, S M; McCarthy, D A; Koepsell, H; Vallon, V; Pollock, C; Panchapakesan, U; Forbes, J M (Sci Rep, 2016)